Đang chuẩn bị liên kết để tải về tài liệu:
Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Recently it has been recognized that stromal markers could be used as a clinically relevant biomarker for therapy response and prognosis. Here, we report on a serum marker for stromal activation, A Disintegrin and Metalloprotease 12 (ADAM12) in colorectal cancer (CRC). |